Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H13NO2.ClH |
| Molecular Weight | 203.666 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@H](N)[C@H](O)C1=CC(O)=CC=C1
InChI
InChIKey=PPRPRPMMKPXRKK-YDYUUSCQSA-N
InChI=1S/C9H13NO2.ClH/c1-6(10)9(12)7-3-2-4-8(11)5-7;/h2-6,9,11-12H,10H2,1H3;1H/t6-,9-;/m0./s1
Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure, is an adrenergic receptor alpha-1 agonist.. Metaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Metaraminol is also used in the treatment of priapism, in spite of this application was not approved, it appears to be effective.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094251 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | METARAMINOL BITARTRATE Approved UseMetaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. |
|||
| Palliative | METARAMINOL BITARTRATE Approved UseMetaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. |
|||
| Palliative | METARAMINOL BITARTRATE Approved UseMetaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. |
|||
| Primary | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 mg 4 times / hour single, intravenous Dose: 10 mg, 4 times / hour Route: intravenous Route: single Dose: 10 mg, 4 times / hour Sources: |
unhealthy, 38 years n = 1 Health Status: unhealthy Age Group: 38 years Sex: F Population Size: 1 Sources: |
Disc. AE: Bigeminal rhythm... AEs leading to discontinuation/dose reduction: Bigeminal rhythm (1 patient) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Bigeminal rhythm | 1 patient Disc. AE |
10 mg 4 times / hour single, intravenous Dose: 10 mg, 4 times / hour Route: intravenous Route: single Dose: 10 mg, 4 times / hour Sources: |
unhealthy, 38 years n = 1 Health Status: unhealthy Age Group: 38 years Sex: F Population Size: 1 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Augmented natriuretic response to infusion of saline in dogs rendered acutely hypertensive with metaraminol. | 1966 Jul |
|
| Myocardial infarction induced by metaraminol bitartrate (aramine). | 1966 Oct |
|
| Pulmonary edema: a complication of metaraminol treatment of paroxysmal supraventricular tachycardia. | 1974 May |
|
| [Prinzmetal's angina induced by dopamine and metaraminol. 2 cases]. | 1979 Mar |
|
| [Metaraminol--an antidote in corpus cavernosum autoinjection therapy-induced prolonged erection]. | 1986 May |
|
| Cerebral arteriovenous malformations, steal, and the hypertensive breakthrough threshold. An experimental study in rats. | 1987 Apr |
|
| An extravascular hydraulic system to control blood pressure by a feedback regulation of the venous return. | 1987 May |
|
| Assessment of the permeability of the blood-retinal barrier in hypertensive rats. | 1987 Oct |
|
| [Metaraminol in therapy of various forms of priapism]. | 1988 Jul |
|
| The metaraminol test and adverse cardiac effects. | 1989 Aug 1 |
|
| [Papaverine-induced priapism. Experiences with a new urologic emergency]. | 1989 Feb 10 |
|
| [Epilepsy and hypertensive crisis after intracavernous injection of metaraminol in the treatment of priapism secondary to a papaverine test]. | 1989 May 20 |
|
| Post-traumatic priapism treated with metaraminol bitartrate: case report. | 1990 Dec |
|
| [Familial Mediterranean fever. The metaraminol test as a cause of severe cephalalgia]. | 1990 Jun |
|
| The effect of intracarotid nonionic contrast media on the blood-brain barrier in acute hypertension. | 1994 Jan |
|
| Reversible segmental left-ventricular dysfunction caused by accidental administration of sympathomimetic drug in human. | 1997 Aug 29 |
|
| Laparoscopic and open surgery for pheochromocytoma. | 2001 |
|
| Anaphylactic or anaphylactoid reactions in patients undergoing cardiac surgery. | 2001 Dec |
|
| Prostaglandin synthesis inhibitor improves hypotension during normothermic cardiopulmonary bypass. | 2001 Nov-Dec |
|
| Pharmacologic exposure of an occult atrial septal defect. | 2001 Sep |
|
| Anesthesia for one-stage bilateral pheochromocytoma resection in a patient with MEN type IIa: attenuation of hypertensive crisis by magnesium sulfate. | 2002 Jan |
|
| Drinking attenuates the noradrenaline release in the lateral hypothalamic area induced by angiotensin II activation of the subfornical organ in rats. | 2003 Mar 18 |
|
| [Preload during spinal anesthesia for cesarean section: comparison between crystalloid and colloid solutions.]. | 2004 Dec |
|
| Use of alpha-agonists for management of anaphylaxis occurring under anaesthesia: case studies and review. | 2004 Dec |
|
| [Experimental study on prevention and treatment of focal segmental glomerulosclerosis with heparin]. | 2004 Jan |
|
| Inadvertent epidural administration of metaraminol. | 2004 Jun |
|
| Cerebellar interpositus nuclear inputs impinge on paraventricular neurons of the hypothalamus in rats. | 2004 Nov 3 |
|
| Photostability of symphatomimetic agents in commonly used infusion media in the absence and presence of bisulfite. | 2004 Nov-Dec |
|
| Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. | 2005 Aug |
|
| Metaraminol (Aramine) in the management of a significant amlodipine overdose. | 2005 Jul |
|
| Use of metaraminol in patients with Familial Mediterranean Fever. | 2006 Aug |
|
| [Diagnosis and treatment of priapism due to neoplasma of penis]. | 2006 Feb |
|
| The blood-brain barrier for catecholamines - revisited. | 2007 Apr |
|
| "Orpheus" cardiopulmonary bypass simulation system. | 2007 Dec |
|
| Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride. | 2007 Oct 15 |
|
| [Diagnosis and treatment of priapism: a report of 15 cases]. | 2008 Sep |
|
| Transient transmural ischaemia during endobronchial laser treatment: possible coronary artery embolism. | 2008 Sep |
|
| Ventricular arrhythmias and antioxidative medication: experimental study. | 2008 Sep-Oct |
|
| Mollaret meningitis may be caused by reactivation of latent cerebral toxoplasmosis. | 2009 |
|
| Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6. | 2009 Aug 15 |
|
| Is propofol a safe and effective sedative for relocating hip prostheses? | 2009 Jan |
|
| Myocardial infarction associated with the administration of intravenous ephedrine and metaraminol for spinal-induced hypotension. | 2009 May |
|
| Impact of admixture time and diluent order on metaraminol concentration. | 2009 Sep |
|
| Vasopressor choice for hypotension in elective Cesarean section: ephedrine or phenylephrine? | 2010 Apr 30 |
|
| Molecular imaging of cardiac sympathetic innervation by 11C-mHED and PET: from man to mouse? | 2010 Aug |
|
| Cardiac arrest in intensive care unit: Case report and future recommendations. | 2010 Jan |
|
| Clinical evaluation of the flotrac/Vigileo system for continuous cardiac output monitoring in patients undergoing regional anesthesia for elective cesarean section: a pilot study. | 2010 Jun |
|
| Adenosine-induced cardiopulmonary arrest in a patient with paroxysmal supraventricular tachycardia--a response. | 2010 May |
|
| Disparities of care for African-Americans and Caucasians with community-acquired pneumonia: a retrospective cohort study. | 2010 May 27 |
|
| [Determination of three adrenergic drugs using capillary electrophoresis with amperometric detection]. | 2010 Nov |
Patents
Sample Use Guides
Intramuscular or Subcutaneous Injection: The recommended dose is 2 to 10 mg (0.2 to 1 mL). As with other agents given subcutaneously, only the preferred sites of injection, as set forth in standard texts, should be used.
Intravenous Infusion: The recommended dose is 15 to 100 mg (1.5 to 10 mL) in 500 mL of Sodium Chloride Injection or 5% Dextrose Injection, adjusting the rate of infusion to maintain the blood pressure at the desired level. Higher concentrations of metaraminol, 150 to 500 mg per 500 mL of infusion fluid, have been used.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23618492
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY | |||
|
5967-52-2
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY | |||
|
DTXSID00975067
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY | |||
|
m7273
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
90698QK27F
Created by
admin on Sat Dec 16 08:53:13 GMT 2023 , Edited by admin on Sat Dec 16 08:53:13 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
